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Abstract 
Objective To investigate whether the risk of incident cardiovascular disease (CVD) is 
increased in patients with prolactinoma.   
Design Population-based, retrospective, open-cohort study using The Health Improvement 
Network (THIN) database. 
Patients 2,233 patients with prolactinoma and 10,355 matched controls (1:5 ratio) from UK 
General Practices contributing to THIN were included. Sex, age, body mass index, and 
smoking status were used as matching parametres. The primary outcome was any incident 
CVD, defined by Read codes suggesting myocardial infarction, angina pectoris, stroke, 
transient ischaemic attack or heart failure. Sex-specific adjusted incidence rate ratios (aIRRs) 
were calculated with Poisson regression, using clinically relevant parameters as model 
covariates. Sensitivity analyses were performed to check whether a change in the initial 
assumptions could have an impact on the findings. 
Results During the 6-year observation period, the composite CVD outcome was recorded in 
54 patients with prolactinoma and 180 “non-exposed” individuals. The incidence rate was 1.8 
and 14.8 per 1000 person-years for the females and males with prolactinoma, respectively. 
The aIRRs for CVD were estimated at 0.99 [95% Confidence Interval (CI): 0.61-1.61, 
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p=0.968)] in female patients and 1.94 (95% CI: 1.29-2.91, p-=0.001) in male patients. These 
findings remained robust in sensitivity analyses restricting to patients with documented 
record of dopamine agonist treatment and those with newly diagnosed prolactinoma. 
Conclusions In contrast to females, men with prolactinoma have increased risk for incident 
CVD; the aetiology of this gender-specific finding remains to be elucidated 
 
Introduction 
Prolactinomas are the most common type of pituitary adenoma with prevalence between 34 
and 44 cases per 100,000 population 
1-5
. Their presenting manifestations relate to the 
consequences of hyperprolactinaemia (hypogonadism, galactorrhea) and to their potential 
mass effects (mostly headaches, visual deterioration and pituitary hormone deficits) 
6
. The 
median age at diagnosis is 31-32 years in females and 39-48 years in males, thereby affecting 
individuals with long life expectancy 
1-3
. The documented diagnostic delay reflecting the 
minimum period to high prolactin (PRL) exposure ranges between 0.5-12 years 
1
, and 
macroadenomas, with the potential to cause various degrees of hypopituitarism, account for 
19-24% of the total cases and up to 75% of the male patients 
1, 2, 5
. First line treatment is 
dopamine agonists, with cabergoline achieving normal PRL in approximately 90% of 
microadenomas and 60-90% of macroadenomas. In cases of resistance or intolerance to 
medical treatment, surgery combined or not with radiotherapy are further options, with 
various success rates and complications 
7-9
   
Apart from the impact on the hypothalamo-pituitary-gonadal axis, untreated 
hyperprolactinaemia has been associated with metabolic derangement and insulin resistance 
10-12
. These observations are consistent with the sympatholytic effects on D2-dopamine 
receptors which are currently studied for the treatment of diabetes mellitus type 2
13, 14
. It has 
been also shown that patients with untreated newly diagnosed prolactinoma demonstrate a 
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hypercoagulable state, reflected in elevated total cholesterol, low density lipoprotein 
cholesterol, apolipoprotein B, platelet count, fibrinogen, plasminogen activator inhibitor-1 
(PAI-1), alongside reduced plasma tissue factor pathway inhibitor levels
15
. However, these 
reports were universally confirmed in the literature
16
.  
Adequately powered studies systematically assessing the risk of cardiovascular disease 
(CVD) in patients with prolactinoma (directly through the hyperprolactinaemia per se or 
indirectly through associated hypopituitarism) are not available. We, thus, for the first time, 
undertook a population-based, retrospective, open cohort study aiming to clarify the long-
term cardiovascular risk in these patients by comparing them to appropriately matched 
controls. 
Materials and Methods 
Study design 
This was a population-based, retrospective, open cohort study in which patients with the 
diagnosis of prolactinoma were compared to age, sex, body mass index (BMI) and smoking 
status matched controls who did not have this diagnosis.   
Source of data  
Patient data was sourced from The Health Improvement Network database (THIN).  THIN 
data are generated from longitudinal data documented in electronic medical records by 
General Practitioners during each episode of consultation using Read Codes (a hierarchical 
coding system for structured storage of information) 
17
.   More than 675 practices, scattered 
representatively around the UK, contribute data to THIN covering 3·7 million active patients 
(6-7% of UK population) 
18
. THIN data are generalizable for the UK for major health 
conditions 
19
 .  
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Selection of the study population 
The study cohort consisted of two sub-cohorts; the “exposed” , including patients diagnosed 
with prolactinoma and the “non-exposed” one (controls, matched on a 5:1 ratio to each 
“exposed” subject) with no diagnosis of prolactinoma before or during the observation 
period. The “exposure” was defined by a Read code specific for prolactinoma (detailed list of 
Relevant Read Codes are available in the Appendix). Records of any dopamine agonist 
treatment (cabergoline, bromocriptine, quinagolide) were also collected. Controls were 
matched to age at index date (to within 1 year), sex, BMI (to within 2 Kg/m2) and smoking 
status (current smoker or not). These matching variables were selected on the basis of 
biological plausibility and relevance to CVD. The main outcome was any new (incident) 
diagnosis of ischaemic heart disease, myocardial infarction, angina pectoris, transient 
ischaemic attack or stroke or incident diagnosis of heart failure or left ventricular dysfunction 
(Supplementary Appendix). Cardiac valve disease was not considered in the analysis. Due to 
power considerations, this was treated as a composite outcome in the analysis. Sex-specific 
data extraction and analyses were performed.  
The THIN data collection scheme received Multi-centre Research Ethics Committee (MREC) 
approval in September 2003 with Scientific Review Committee (SRC) approval of this study 
protocol in March 2015 (Ref: SRC13-080). 
Observation period 
The study period was set from 1
st
 Jan 1990 to 1
st
 September 2015. Each patient diagnosed 
with a prolactinoma was followed up from their index date (start of observation at the patient 
level) until the patient died, left the Practice, the Practice ceased data collection or a positive 
study outcome (cardiovascular event) was recorded. Patients with CVD recorded any time 
prior to the index date (at baseline) were excluded from the study (only incident CDV was 
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considered). Observation period and study entry requirements were identical in the control 
cohort.  
Sensitivity and subgroup analyses 
Given the observational nature of the evidence, sensitivity analyses were performed aiming to 
check whether a change in the initial assumptions could have an impact on the findings. 
Thus, an alternative definition of “exposure”, namely a Read code specific for prolactinoma 
and a concurrent documented treatment with any dopamine agonist, was used in a sensitivity 
analysis to further consolidate the diagnosis of prolactinoma. Furthermore, a sensitivity 
analysis was also undertaken limiting to those patients with an incident diagnosis of 
prolactinoma (patients with a new diagnosis after joining Practice) and their respective 
controls aiming to diminish the bias associated with the inclusion of prevalent cases. Finally, 
since prolactinomas are diagnosed at an earlier age in women 
1, 2
, a subgroup analysis 
limiting to those female patients aged above 45 years and their respective controls was also 
undertaken to offset any bias related to the low risk for CVD in premenopausal women. 
Statistical analyses 
Baseline characteristics (age, follow-up period, sex, Townsend deprivation index 
20
, BMI, 
smoking status, presence of hypertension or diabetes mellitus and use of lipid lowering 
medications) were descriptively analysed. Comparison of baseline characteristics between 
“exposed” and “non-exposed” groups was performed by appropriate descriptive statistics 
(Chi-squared, Student’s t or Mann-Whitney U tests). 
Crude (unadjusted) incidence rate ratios (IRRs) were calculated for each outcome. Adjusted 
incidence rate ratios (aIRRs) were calculated using Poisson regression model adjusting for 
patient level covariates.  Covariate adjustment analysis was conducted to address the 
potential impact of imbalance in baseline characteristics. Covariates were age, sex, categories 
of BMI (<25, 25-29.9, ≥30 Kg/m2 and missing values groups), deprivation quintiles, 
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hypertension, diabetes mellitus, use of lipid lowering medications and smoking status. IRRs 
were calculated with 95% confidence intervals (CI) and a statistical significance threshold 
taken to be p<0.05. Applying multiple significance tests was avoided to minimise inflation of 
alpha error 
21
 and as per recommendation of the RECORD guideline for reporting 
epidemiological studies using routinely collected data 
22
. All statistical analyses were 
performed using Stata 14.0 software (StataCorp. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP) 
Results 
Baseline characteristics 
A total of 2,233 prevalent (diagnosed before the index date) and incident (diagnosed after the 
index date) patients with prolactinoma (1,822 females and 411 males) and no history of CVD 
at baseline were identified. After the identification of the “exposed” patients, out of the pool 
of individuals with no prolactinoma, a total of 10,355 subjects (8,557 females and 1,798 
males) were randomly selected on 1:5 ratio, matching on sex, age, BMI and smoking status.   
The study population consisted of a total of 12,588 individuals (10,379 females and 2,209 
males) with  mean age  37.1 (SD 10.2) and 47.3 (SD 14.4) years for females and males, 
respectively. The baseline characteristics of the subjects of the study are shown in Table 1. 
There was no significant difference in age, smoking status, presence of hypertension or use of 
lipid lowering medications between the “exposed” and “non-exposed” cohort at baseline. 
Although BMI was matched to within 2 Kg/m2 between the “exposed” and “non-exposed” 
individuals, this was marginally but statistically different between the two groups for both 
males and females as a result of the large sample size.  Diabetes mellitus was significantly 
more frequent in the “non-exposed” subjects. The potential impact of these imbalances was 
further addressed by covariate adjustment analysis.   
Main Outcome 
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During the observation period, the composite CVD outcome was recorded in 54 (20 females 
and 35 males) patients with prolactinoma and 190 (103 females and 87 males) “non-exposed” 
individuals. The incidence rate for the “exposed” females was 1.8 per 1000 person-years 
compared to 2.0 per 1000 person-years for the “non-exposed” females. The incidence rate for 
the “exposed” males was 14.8 per 1000 person-years compared to 8.7 per 1000 person-years 
for the non-exposed” males.  
The crude (unadjusted) IRR for CVD in female patients compared to matched controls was 
estimated at 0.90 [95% CI: 0.56-1.45, p=0.666].  After adjusting for age, gender, deprivation 
quintiles, BMI groups, hypertension, smoking, lipid lowering medications and diabetes 
mellitus, the aIRR was found to be similar and was estimated at 0.99  (95% CI: 0.61-1.61, 
p=0.968).  
The crude IRR for CVD in male patients with prolactinoma was found to be significantly 
higher compared to matched controls and was estimated at 1.72 (95% CI: 1.16-2.55, 
p=0.001).  After covariate adjustment, the aIRR changed minimally and was estimated at 
1.94 (95% CI: 1.29-2.91, p=0.001).  The findings of the above analyses are presented in 
detail in Supplementary Appendix.  
Sensitivity and subgroup analyses 
Excluding patients with no record of dopamine agonist treatment and their respective controls 
did not alter the main findings:  aIRR was calculated at 1.13 (95% CI: 0.61-2.09, p=0.689) 
for female and 1.98 (95% CI: 1.27-3.09, p=0.002) for male patients. A detailed presentation 
of this analysis is shown in Table 2. Sensitivity analysis limiting to incident cases and their 
respective controls revealed similar findings:  aIRR was estimated at 1.04 (95% CI: 0.54-
2.03, p=0.894) for female patients and 2.00 (95% CI: 1.14-3.49, p=0.019) for male patients. 
A detailed presentation of this analysis is shown in Table 2. Sensitivity analysis treating each 
component of the composite cardiovascular outcome as a separate outcome (namely 
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ischaemic heart disease, stroke/TIA, heart failure/left ventricular dysfunction) revealed that 
the results were consistent in both male and female patients. Similarly, the exclusion of two 
patients with concurrent acromegaly did not alter the findings. Routine surveillance for 
cardiac valve disease in some patients with prolactinoma may have resulted in high detection 
of left ventricular dysfunction. However, excluding heart failure from our composite outcome 
did not alter our findings. Finally, when analysis was restricted to those female patients 
diagnosed with prolactinoma who are above 45 years and their respective controls, the IRR 
was at 1.02 (95% CI: 0.54 – 1.90, p=0.95). 
 
Discussion 
This is the first population-based, retrospective, open cohort study looking systematically at 
the cardiovascular morbidity in patients with prolactinoma. We have shown that males have a 
higher incidence of CVD compared to matched subjects without this diagnosis over a six year 
observation period (IRR 1.72 (95% CI: 1.16–2.55, p=0.001)]. In contrast, there is no 
evidence to suggest an increase in the risk of CVD in female patients with prolactinoma. 
These findings were also confirmed after adjustment for clinically significant covariates and 
remained robust in sensitivity analyses. 
Studies systematically assessing the risk of CVD in adequately powered sample of patients 
with prolactinoma are not available. Possible mechanisms affecting the cardiovascular 
morbidity in this group of patients include a direct effect of hyperprolactinaemia, as well as 
the impact of potential pituitary hormone deficits and/or their management.  
In population-based studies, it has been previously shown that the levels of PRL associate 
positively with inflammatory biomarkers (such as interleukin-6) 
23
, adverse cardiovascular 
risk profile 
15
 and increased cardiovascular mortality 
24
. Furthermore, particularly in patients 
with untreated prolactinoma, a range of metabolic disorders (including insulin resistance, 
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elevated total cholesterol, low density lipoprotein cholesterol, apolipoprotein B), deranged 
fibrinolysis (platelet count, fibrinogen, PAI-1 and PAI-1/ tissue plasminogen activator ratios), 
as well as evidence of preclinical atherosclerosis have been reported 
10-12, 25-28
. Although the 
duration of hyperprolactinaemia is not known in our cohort of prolactinoma patients, 
published literature suggests diagnostic delays ranging between 0.5-12 years reflecting the 
minimum period of exposure to high PRL
1
. Whether the impact of previous 
hyperprolactinaemia on the cardiovascular system is reversible or persists despite treatment 
with dopamine agonists remains to be elucidated.  
Interestingly, we found that the increased risk for CVD in male patients persisted even in the 
presence of concurrent documented treatment with dopamine agonist; the inclusion of cases 
with suboptimal biochemical control (due to resistance, intolerance or non-compliance) 
cannot be excluded, particularly given that male gender has been independently associated 
with resistance to cabergoline 
29
.  It should be also noted that the duration of exposure to high 
PRL levels may be a significant effect modifier, which is particularly relevant when 
investigating outcomes like CVD and may provide a possible explanation for the gender 
differences we identified. In line with this, males are diagnosed at an older age than females, 
possibly implying longer diagnostic delay and exposure to the consequences of 
hyperprolactinaemia and of related hypogonadism
1
. “Interestingly, a recent retrospective 
cohort study including approximately 373 individuals with hyperprolactinemia (irrespective 
of its primary aetiology) reported similar findings with our study 
30
. In this report, male 
hyperprolactinaemic patients had a higher IRR for cardiovascular and all-cause mortality in 
contrast to female patients, in whom no difference was noted when compared to 
normoprolactinaemic controls 
30
. Of note, an older study of a case-control design which 
explored prolactin levels in those who suffered a coronary artery event and controls did not 
find higher prolactin levels in the affected patients 
31
. This was the case (non-significant 
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findings) in another study of a cohort design, however the hyperprolactinaemic patients were 
few 
32
 and possibly the study was underpowered. 
Hypopituitarism is associated with increased cardiovascular morbidity 
33
 and is diagnosed in 
patients with adenomas large enough to cause damage to the normal adenohypophyseal cells. 
A limitation of the present study was the inability to discriminate between micro- or 
macroprolactinomas. However, given that macroprolactinomas are more common in males 
1
, 
the possibility that men with prolactinoma are most likely to have hypopituitarism, cannot be 
excluded; this hypothesis can provide a further explanation on our gender-specific findings. 
In this line of thought, it would be clinically relevant to include a control group with patients 
diagnosed with non-functioning pituitary adenoma. Unfortunately, this was not currently 
feasible in the THIN database. 
Analysis restricted to those female patients who are aged above 45 years and their respective 
controls still did not confirm high IRR for CVD [1.02 (95% CI: 0.54 – 1.90, p=0.95)]. 
Whether a longer duration of follow-up would alter these results needs to be clarified.  
The advantages of our study are that it is population-based with large sample size and 
appropriate matching for confounding factors. Furthermore, we performed sensitivity 
analyses, which enhanced the validity of the original results. Limitations include the lack of 
detailed clinical phenotyping (adenoma size, pituitary dysfunction and its management, 
response to dopamine agonist treatment, other treatments used for the prolactinoma), which 
would allow further clarification of the pathogenetic mechanisms of our findings. Moreover, 
it should be noted that patients with a documented history of CVD event preceding the index 
date were excluded from the study to ensure outcomes could be attributable to the diagnosis 
of prolactinoma and not to other pre-existing risk factors of CVD. This may have resulted in 
a population at low risk for CVD, which may not be reflective of the general population of 
patients with prolactinoma. Finally, the validity of prolactinoma-related recordings is not 
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fully documented in THIN as yet. Nonetheless, large well-characterised patient registries may 
facilitate this in the future and will also allow causal interpretation of our observational data.  
In conclusion, in a population-based, retrospective cohort study of 12,588 subjects, we have 
found that incident CVD is increased only in men with prolactinoma. Long-standing 
hyperprolactinaemia and its consequences, as well as hypopituitarism and its management 
may be the underlying mechanisms. The impact of these findings on the long-term mortality 
of these patients remains to be reviewed.  
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Tables 
Table 1:  Baseline characteristics of study population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results for continuous variables are presented as mean (standard deviation) and for dichotomous and ordinal variables as N (%).  A high Townsend index is 
indicative of high material deprivation. The index is assigned to each patient record based on their residential postcode. For diabetes mellitus, hypertension and 
smoking status, a positive documentation in the General Practice records was considered as presence of the risk factor. * Statistically significant at 0.05 
 Females (n=10,379) Males (n=2,209) 
 Prolactinoma subjects “Non-exposed” 
subjects 
Prolactinoma subjects “Non-exposed” 
subjects 
Number of subjects 1,822 8,557 411 1,798 
Follow-up period (years)* 6.1 [5.2] 6.0 [4.9] 5.6 [4.7] 5.6 [4.6] 
Age (years)* 37.1 (10.2) 37.1 (10.2) 47.2 (14.5) 47.4 (14.4) 
Body mass index* 26.7 (6.3) 26.0 (5.4)* 29.6 (6.1) 28.1 (4.6)* 
Current smoking 276 (15.2) 1,237 (14.5) 63 (15.3) 267 (14.85) 
Hypertension 95 (5.2) 510 (6.0) 65 (15.8) 333 (18.5) 
Lipid lowering medications 53 (2.9) 278 (3.3) 55 (13.4) 264 (14.7) 
Diabetes mellitus 24 (1.3) 217 (2.5)* 19 (4.6) 148 (8.2)* 
Townsend index     
(Least deprived) 1 416 (22.8) 1,932 (22.6)* 111 (27.0) 447 (24.9) 
2 324 (17.8) 1,711 (20.0) 90 (21.9) 416 (23.1) 
3 414 (22.7) 1,749 (20.4) 90 (21.9) 356 (19.8) 
4 348 (19.1) 1,643 (19.2) 52 (12.7) 305 (16.9) 
5 189 (10.4) 1,008 (11.8) 38 (9.2) 186 (10.3) 
Not available 131 (7.2) 514 (6.0) 30 (7.3) 88 (4.9) 
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Table 2: Sensitivity analyses restricting to those with evidence of treatment with dopamine agonist or incident diagnosis of prolactinoma and their 
respective controls 
 
*Adjusted for age, gender, deprivation quintiles, body mass index (BMI) group, hypertension, smoking, lipid lowering medications and diabetes 
mellitus.  The BMI categories (kg/m
2
) were <25, 25-29.9, ≥30 and missing values groups. P - values were derived from Poisson regression. CI: 
Confidence Interval,  IRR: Incidence Rate Ratio 
Female patients with 
evidence of dopamine 
agonist therapy 
Male patients with evidence of 
dopamine  agonist therapy 
Incident female patients Incident male patients  
 Prolactinoma  
subjects 
“Non-
exposed” 
cohort 
Prolactinoma 
subjects 
“Non-
exposed 
cohort” 
Prolactinom
a subjects 
“Non-exposed” 
cohort 
Prolactinoma 
subjects 
“Non-
exposed” 
cohort 
Number of 
subjects 
1,312 6,147 353 1,546 795 3,718 232 1,025 
Person-years 8,331 37,092 2,006 8,732 5,291 23,138 1,259 5,421 
Incident 
cardiovascular 
disease 
13 53 29 74 11  50 18  52 
Incidence Rate 
(per 1000 
person-years) 
1.6 1.4 14.5 8.5 2.1 2.2 14.3 9.6 
IRR (95% CI) 1.09 (0.60-2.00) 1.70 (1.11-2.62) 0.96 (0.50-1.85) 1.49 (0.87-2.55) 
p 0.776 0.015 0.907 0.145 
Adjusted IRR 
(95% CI)* 
1.13 (0.61-2.09) 1.98 (1.27-3.09) 1.04 (0.54-2.03) 2.00 (1.14-3.49) 
p 0.689 0.002 0.894 0.019 
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Contents 
 Further methodological details on the construction of the cohort 
 Summary of the Read codes used for the study 
 Supplementary Table: Risk of incident cardiovascular disease on the basis of 
prolactinoma diagnosis 
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Further methodological details on the construction of the cohort 
 
 The index date for each exposed patient (start date of patient-specific 
observation) was set at one year after registration with the Practice (if the 
patient was already diagnosed with prolactinoma and the Practice was eligible 
for inclusion in THIN) or the date the Practice became eligible for 
participation (if the patient was already diagnosed with prolactinoma and the 
Practice initially not eligible) or the date of the first diagnosis (incident 
patients with prolactinoma), whichever was the latest. 
 Individual Practices (already included into the THIN network) were eligible 
for inclusion in the study from the later of the following two dates: one year 
after the date their Practice system was installed; and the Practice’s acceptable 
mortality recording (AMR) date (a measure of quality of the data). This 
approach ensured that any selected Practice was making full use of their 
system and was not under-recording important outcomes. This minimum entry 
period of one year from the patient’s Practice registration date was applied to 
maximise the likelihood that each case had sufficient time to have their 
baseline characteristics and comorbidities recorded in the system. 
 A minimum one year entry period after registration with the Practice described 
above was applied in the controls (“non-exposed patients) as well. Individuals 
were followed up until death, departure from Practice, cessation of Practice 
data collection or positive outcome (incident cardiovascular event). Similarly, 
any control patient who had the outcome of interest preceding the index date 
was also excluded from the study. 
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Summary of the Read codes used for the study  
Exposure: BB5y400 (prolactinoma) 
Outcomes:  
 
 
 
 
Page 20 of 21Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Supplementary Table: Risk of incident cardiovascular disease on the basis of prolactinoma diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted for age, gender, deprivation quintiles, body mass index (BMI) group, hypertension, smoking, lipid lowering medications and diabetes 
mellitus.  The BMI categories  (kg/m
2
) were <25, 25-29.9, >=30 and missing values groups. P-values were derived from Poisson regression. 
 Females Males 
 Prolactinoma “Non-exposed” 
cohort 
Prolactinoma “Non-exposed” 
cohort 
Number of patients 1,822 8,557 411 1,798 
Incident cardiovascular disease 20  103  34 87 
Person-years 11,112 51,489 2,287 10,052 
Incidence Rate (per 1000 person-years) 1.8 2.0 14.8 8.7 
Incidence Rate Ratio (95% CI) 0.90 (0.56-1.45) 1.72 (1.16-2.55) 
p 0.666 0.007 
Adjusted Incidence Rate Ratio (95% CI) 
 
0.99 (0.61-1.61) 1.94 (1.29-2.91) 
p- 0.968 0.001 
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